BC Cancer-Vancouver Centre

Vancouver, British Columbia V5Z 4E6

2 studies enrolling now · 6 studies all time

What they study most

Adult T Cell Leukemia/Lymphoma, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations, Locally Advanced or Metastatic Solid Tumors, Mantle-Cell Lymphoma, Metastatic Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer, PIK3CA-Mutated Cancers, Relapsed/Refractory Peripheral T-Cell Lymphoma, Renal Cell Carcinoma

Studies at this site

• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Recruiting now
• A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) — Running, not enrolling
• A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers — Running, not enrolling
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma — Completed
• Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) — Completed